APA (7th ed.) Citation

IM, J., S, B., P, M., P, T., SD, R., G, G., . . . GR, F. (2023). The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. Journal of viral hepatitis, 30(5), 448. https://doi.org/10.1111/jvh.13814

Chicago Style (17th ed.) Citation

IM, Jacobson, et al. "The Tolerability of Sofosbuvir/velpatasvir for 12 weeks in Patients Treated in the ASTRAL 1, 2 and 3 Studies: A Pooled Safety Analysis." Journal of Viral Hepatitis 30, no. 5 (2023): 448. https://doi.org/10.1111/jvh.13814.

MLA (9th ed.) Citation

IM, Jacobson, et al. "The Tolerability of Sofosbuvir/velpatasvir for 12 weeks in Patients Treated in the ASTRAL 1, 2 and 3 Studies: A Pooled Safety Analysis." Journal of Viral Hepatitis, vol. 30, no. 5, 2023, p. 448, https://doi.org/10.1111/jvh.13814.